Jess Hundal
About Jess Hundal
Jess Hundal serves as the Executive Director at Kite Pharma, a position he has held since 2020. He has extensive experience in the pharmaceutical industry, having previously worked at Novartis, Celgene, and Bristol-Myers Squibb in various leadership roles.
Work at Kite Pharma
Jess Hundal has been serving as the Executive Director at Kite Pharma since 2020. In this role, Hundal is involved in overseeing various initiatives within the organization, contributing to the development and commercialization of innovative therapies. Kite Pharma is known for its focus on cell therapy, particularly in the treatment of cancer, and Hundal's leadership plays a key role in advancing the company's objectives.
Previous Experience at Novartis
Before joining Kite Pharma, Jess Hundal worked at Novartis as a Clinical Auditor from 1992 to 2004. During this 12-year tenure in the Greater New York City Area, Hundal was responsible for ensuring compliance with clinical trial regulations and standards, contributing to the integrity of clinical data and processes.
Career at Celgene
Jess Hundal held the position of Executive Director at Celgene from 2004 to 2019, a period of 15 years in the Greater New York City Area. In this capacity, Hundal was instrumental in leading various projects and initiatives that supported the company's mission in developing therapies for cancer and inflammatory diseases.
Experience at Bristol-Myers Squibb
Following his time at Celgene, Jess Hundal worked as an Executive Director at Bristol-Myers Squibb for 9 months in Summit, New Jersey, from 2019 to 2020. In this role, Hundal contributed to the company's strategic initiatives and operational excellence in the pharmaceutical sector.
Education in Cellular and Molecular Biology
Jess Hundal earned a Bachelor of Science degree in Cell/Cellular and Molecular Biology from The University of Kansas, studying from 1980 to 1986. This educational background provided Hundal with a strong foundation in the biological sciences, which has been essential throughout his career in the pharmaceutical industry.